| scholarly article | Q13442814 |
| P50 | author | Daniel Gonzalez | Q86888058 |
| P2093 | author name string | Jian Wang | |
| Lei Zhang | |||
| Fang Wu | |||
| Gilbert J Burckart | |||
| Jeffrey Fisher | |||
| Peng Duan | |||
| Victor Crentsil | |||
| Jason N Moore | |||
| P2860 | cites work | Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling | Q23924161 |
| Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification | Q28088352 | ||
| Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. | Q31096663 | ||
| Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents | Q33355914 | ||
| Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children | Q33998916 | ||
| Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein | Q34107284 | ||
| Physiologically based pharmacokinetic modeling and simulation in pediatric drug development | Q34658074 | ||
| Clinical pharmacology of paracetamol in neonates: a review. | Q35086268 | ||
| A Multicenter, Randomized, Open-Label, Pharmacokinetics and Safety Study of Pantoprazole Tablets in Children and Adolescents Aged 6 Through 16 Years With Gastroesophageal Reflux Disease | Q35308159 | ||
| Dose estimation for children | Q35598801 | ||
| PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. | Q35952367 | ||
| CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers | Q36164941 | ||
| A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam | Q36910537 | ||
| Stereoselective disposition of proton pump inhibitors | Q37136970 | ||
| Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children | Q37279407 | ||
| Drug labeling and exposure in neonates | Q37591097 | ||
| Physiologically based pharmacokinetic (PBPK) modeling in children | Q38016332 | ||
| Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age. | Q38467234 | ||
| Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions | Q39240124 | ||
| Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor | Q39643626 | ||
| Pharmacokinetics of pantoprazole in man. | Q41102721 | ||
| Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model | Q41559765 | ||
| Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs | Q42552393 | ||
| Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease | Q42608396 | ||
| The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel | Q42728694 | ||
| Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD). | Q43122470 | ||
| Developmental expression of human hepatic CYP2C9 and CYP2C19. | Q44666457 | ||
| Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens | Q44787212 | ||
| A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects | Q45172356 | ||
| Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study | Q46884816 | ||
| Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants | Q48076685 | ||
| Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling | Q48463862 | ||
| Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions | Q48567088 | ||
| Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments | Q49330212 | ||
| Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children | Q50062507 | ||
| Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. | Q51796989 | ||
| Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. | Q51975107 | ||
| Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. | Q52067661 | ||
| A review of developmental aspects of cytochrome P450. | Q52181487 | ||
| Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects | Q70493587 | ||
| Pharmacokinetics of pantoprazole in man | Q71342694 | ||
| Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions | Q84411485 | ||
| Neonatal and pediatric clinical pharmacology | Q87409957 | ||
| Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents | Q87812592 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 158-166 | |
| P577 | publication date | 2018-12-05 | |
| P1433 | published in | CPT: pharmacometrics & systems pharmacology | Q27724610 |
| P1476 | title | Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition | |
| P478 | volume | 8 |
Search more.